Lauri Diehl

Executive Director, Research Pathology Gilead Sciences

Seminars

Wednesday 7th October 2026
Panel Discussion: From Discovery to Deployment: How Frontier Tissue AI Augments Biomarker Development & Accelerates the Path to Bedside
11:20 am
  • One Frontier Model, For Every Stage of Drug Development: Discover how a unified ecosystem powered by a single frontier AI model streamlines biomarker discovery, clinical trial stratification, regulatory-grade diagnostics, and global deployment to pathology labs. Platform agnostic development under one roof – no need for algorithm hand-offs or tedious integrations before deployment
  • De-Risking CDx Timelines With Tissue AI: AI-driven biomarker signal detection reduces trial enrollment risk and enables more informed decisions from less tissue — shortening Rx-Dx co-development time
  • Redefining Global Pathology Routine: Moving tissue biomarkers from isolated reference labs to global clinical routine powered by our extensive CRO partnerships and an active lab network
Wednesday 7th October 2026
Promise & Pitfalls of Tumor Target Quantification in Antibody-Drug Conjugate & Immune Cell Engager Drug Development
2:40 pm
  • Target expression in indication selection and as potential predictive biomarkers
  • Digital pathology approaches and technical challenges
  • Optimizing program investment and deciding what data will be enough
Lauri_Diehl[1]
View all Speakers
View Event Brochure